The FDA tried to ease the concerns of drugmakers Thursday when it said that companies working on a new class of cholesterol-lowering drugs known as PCSK9 inhibitors, may not have to prove they also...
Tantalized by various megablockbuster projections for the PCSK9 field of cholesterol drugs, Pfizer has mapped out one of the most ambitious late-stage programs in the industry for RN-316.
Merck's experimental anacetrapib is one of those massively expensive lottery programs that can spur dreams of huge revenue streams.
Alnylam is pushing its latest RNAi drug through early clinical trials, highlighting the company's delivery platform that enables an effective gene-silencing treatment. This time, the RNA specialist published results from a successful Phase I study of its cholesterol drug ALN-PCS.
Isis Pharmaceuticals has revealed more enticing details about its midstage program for a blood fat-lowering drug. After wowing investors with data from a Phase II study in diabetics last month, Isis has served up another round of promising results from a small trial of the therapy in patients with high triglycerides on fibrates.
One of the hottest competitions in drug development has spurred Amgen, Sanofi and Pfizer to invest heavily in PCSK9 drug programs aimed at lowering bad cholesterol in a way that could prove a game-changer in the field of heart disease.
Resverlogix fell hard this afternoon on news that the company fell short in a midstage study of its lead HDL cholesterol-boosting drug. The Calgary-based biotech company said the Phase IIb study of RVX-208 failed to meet the goal of change in percent of atheroma volume in patients with a high risk of developing cardiovascular disease.
Researchers have found an RNA molecule that interferes with the production of lipoproteins, which could provide the basis for new therapies to treat high cholesterol.
Cadila Healthcare wants to partner with Big Pharma. The Indian drugmaker won domestic approval for a brand-new drug for diabetics, Lipaglyn, that it's prepared to launch in its own country later this year. But it wants to take the drug worldwide--and into blockbuster territory--with the help of a marketing partner.
No question, statins are the big gorilla of the cholesterol-fighting drug market. And as Forbes reports today, that drug class is marking out an even bigger territory as time goes by. Over the past 5 years, statin prescriptions have grown by 17% to 214 million a year, while other cholesterol remedies lost 28% of their scripts. Now, those other drugs only account for 50 million prescriptions a year.